VERVE THERAPEUTICS IN

Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023

26 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

21 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer

18 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results

10 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference

03 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

Verve Establishes Global Collaboration with Lilly to Advance Verve’s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease

15 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

01 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day

23 May 2023 06:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results

15 May 2023 06:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference

09 May 2023 06:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day

27 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates

03 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

02 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia

14 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in Upcoming Investor Conferences

11 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results

07 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data in Circulation and Presentations at the American Heart Association Annual Meeting

31 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in Upcoming Investor Conferences

22 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia

21 Sep 2022 06:30:00 By Nasdaq GlobeNewswire